Loading…
No business profile yet.
Size Odyssey Therapeutics (ODTX) is a United States Health Care company (Biotechnology) with a market value of $924M, the 2298th largest of 3,117 United States companies the cockpit tracks. Shares closed at $19.23 on 6 Nov 2026.
Growth Revenue fell 33.5% over the last twelve months (peer median +0.6%); the operating margin is -5,415.2% (peer median -24.8%).
Valuation It trades at 208.9× enterprise value to sales against a peer median of 7.1× (3rd most expensive of 19).
Capital Return on invested capital runs 193.3 points below its cost of capital (19.5% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | $2.98M | $4.47M | $1.04M | $0 |
| Revenue growth | — | -33% | +331% | — | — |
| Gross profit | n/a | -$1.94M | -$721,000 | -$3.87M | -$2.76M |
| EBITDA | n/a | -$156M | -$130M | -$129M | -$120M |
| Net income | n/a | -$149M | -$129M | -$126M | -$125M |
| Free cash flow | n/a | -$131M | -$118M | -$118M | -$113M |
| Capital expenditure | n/a | $1.23M | $764,000 | $5.06M | $13.0M |
| Total debt | $23.5M | $27.1M | $31.0M | $34.4M | $40.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ODTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.1% | -5.4% | 5th highest of 21 |
| Distance from 52-week high | -33.8% | -41.2% | 6th highest of 21 |
| Revenue growth (TTM) | -33.5% | +0.6% | 3rd lowest of 18 |
| Operating margin | -5,415.2% | -24.8% | 2nd lowest of 19 |
| EV / Sales | 208.9× | 7.1× | 3rd most expensive of 19 |
| ROIC minus cost of capital | -193.3 pp | -7.5 pp | lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | 10.0× | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% | -16.6% |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |